



Please complete ALL information below and fax your request to 1-888-671-5285

Sprycel® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required) Provider Information (required)

Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)

Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if generic substitution is acceptable		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)

Select the diagnosis below:

Acute lymphoblastic leukemia/acute lymphoblastic lymphoma (ALL)

Chronic myelogenous/myeloid leukemia (CML)

Other diagnosis: _____ ICD-10 Code(s): _____

Prescriber's Specialty:
Is Sprycel prescribed by or in consultation with an oncologist and/or hematologist? Yes No

Acute Lymphoblastic Leukemia/Acute Lymphoblastic Lymphoma (ALL):
Does the patient have Philadelphia chromosome-positive (Ph+)/BCR ABL acute lymphoblastic leukemia (ALL)? Yes No
Has the patient experienced resistance or intolerance to any prior therapy? Yes No
For pediatric patients (under 18 years of age):
Is this a newly diagnosed disease? Yes No
Will Sprycel be used in combination with chemotherapy? Yes No

Chronic Myelogenous/Myeloid Leukemia (CML):
Does the patient have Philadelphia chromosome-positive (Ph+)/BCR ABL chronic myelogenous/myeloid leukemia (CML)? Yes No
Does the patient have the T315I, F317L, and V299L mutation? Yes No

Reauthorization:
Does the patient show evidence of progressive disease while on Sprycel therapy? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of FutureScripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.
Office use only: Sprycel_FSP_2019Apr-W